Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study

被引：0
|
作者：
B. Wolnik
A. Hryniewiecki
D. Pisarczyk-Wiza
T. Szczepanik
T. Klupa
机构：
[1] Medical University of Gdańsk,Department of Hypertension and Diabetology
[2] Sanofi-Aventis Poland,Diabetes Division
[3] Medical University of Poznan,Department of Internal Diseases and Diabetology
[4] Starkiewicz Hospital,Zaglebie Oncology Center
[5] Jagiellonian University Medical College,Department of Metabolic Diseases
来源：
Diabetes Therapy | 2022年 / 13卷
关键词：
Type 2 diabetes; Elderly; Hypoglycemia; Insulin; NPH; Glargine 300;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 310
页数：9
相关论文
共 50 条
  • [1] Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study
    Wolnik, B.
    Hryniewiecki, A.
    Pisarczyk-Wiza, D.
    Szczepanik, T.
    Klupa, T.
    DIABETES THERAPY, 2022, 13 (02) : 301 - 310
  • [2] OLDER PEOPLE WITH TYPE 2 DIABETES BENEFIT MORE AFTER SWITCHING FROM NPH INSULIN TO GLARGINE 300 U/ML: POST-HOC ANALYSIS OF A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL STUDY
    Wolnik, B.
    Hryniewiecki, A.
    Pisarczyk-Wiza, D.
    Szczepanik, T.
    Klupa, T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A92 - A92
  • [3] Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
    Wolnik, B.
    Wiza, D.
    Szczepanik, T.
    Syta, A.
    Klupa, T.
    JOURNAL OF DIABETES RESEARCH, 2020, 2020
  • [4] GLYCAEMIC VARIABILITY AND TIME-IN-RANGE DURING SELF-TITRATION OF ONCE DAILY INSULIN GLARGINE 300U/ML VERSUS NPH (NEUTRAL PROTAMINE HAGEDORN) INSULIN IN INSULIN-NAIVE CHINESE TYPE 2 DIABETES PATIENTS
    Ling, J.
    Ozaki, R.
    Luk, A.
    Chan, J.
    Chow, E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A23 - A24
  • [5] Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study
    Chen, Liming
    Wan, Hailong
    Han, Jie
    Yang, Caixian
    Shao, Hailin
    Li, Jialin
    Yan, Wensheng
    Xiao, Jianzhong
    Sun, Yadong
    Li, Min
    Han, Yanfang
    Kang, Lei
    Zhang, Minlu
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1423 - 1431
  • [6] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [7] Comparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysis
    Lee, Pearl
    Chang, Annette
    Blaum, Caroline
    Vlajnic, Aleksandra
    Gao, Ling
    Halter, Jeffrey
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (01) : 51 - 59
  • [8] Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy
    Bellia, Alfonso
    Babini, Anna C.
    Marchetto, Paolo E.
    Arsenio, Leone
    Lauro, Davide
    Lauro, Renato
    ACTA DIABETOLOGICA, 2014, 51 (02) : 269 - 275
  • [9] Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy
    Alfonso Bellia
    Anna C. Babini
    Paolo E. Marchetto
    Leone Arsenio
    Davide Lauro
    Renato Lauro
    Acta Diabetologica, 2014, 51 : 269 - 275
  • [10] Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
    Rosenstock, J.
    Fonseca, V.
    McGill, J. B.
    Riddle, M.
    Halle, J. P.
    Hramiak, I.
    Johnston, P.
    Davis, M.
    DIABETOLOGIA, 2009, 52 (09) : 1971 - 1973
12345